|
Observed and expected cancer cases among digitoxin users. |
|||||
| ICD-10 |
Site |
Sex |
Observed |
Expected |
SIR (95 % CI) |
|
|
|||||
| C50 |
Breast |
F |
57 |
45.7 |
1.25(0.95, 1.62) |
| C61 |
Prostate |
M |
108 |
86.7 |
1.25(1.03, 1.50) |
| C18–21 |
Colo-rectal |
M+F |
127 |
98.5 |
1.29(1.06, 1.51) |
| C32–34 |
Lung |
M+F |
63 |
46.4 |
1.35(1.04, 1.74) |
| C64,C65,C67,C68 |
Kidney, urinary |
M+F |
59 |
51.8 |
1.14(0.87, 1.47) |
| C43.C44 |
Melanoma, other skin |
M+F |
61 |
49.7 |
1.23(0.94, 1.58) |
| C81–C85,C88–C92 |
Leukemia/Lymphoma |
M+F |
53 |
37.5 |
1.41 (1.06, 1.85) |
| C00–C97 |
All sites |
M+F |
641 |
502.8 |
1.27(1.18, 1.37) |
|
Observed and expected cancer cases amoung digitoxin users, and standardized incidence ratio (SIR) presented for all types of cancers having more than 30 expected cases. The cancer types are divided in the groups according to ICD-10 (International Classification of Disease).Observed=cancer cases in the population on digitoxin after start on the drug,no lag time applied. Expected=expected cancer cases calculated by applying the national cancer rates matched exactly on year of birth,age and sex. | |||||
Haux et al. BMC Cancer 2001 1:11 doi:10.1186/1471-2407-1-11 |
|||||